🔥 Trending Takeda's Qdenga: India Approves First Dengue Vaccine

Takeda's QDENGA (TAK-003) is a dengue vaccine that has recently gained significant attention for its role in preventing dengue disease. It represents a crucial advancement in global public health efforts, particularly in regions where dengue is endemic ⁶.

What is QDENGA (TAK-003)?

QDENGA is a live-attenuated tetravalent vaccine designed to protect against all four serotypes of the dengue virus ⁸. This means it aims to provide immunity against Dengue virus serotypes 1, 2, 3, and 4. The vaccine works by stimulating the immune system to produce antibodies against these serotypes, thereby preparing the body to fight off a future dengue infection ⁹.

A key feature of QDENGA is its approval for use regardless of prior dengue exposure, meaning pre-vaccination testing is not required ². This simplifies the vaccination process and expands its accessibility to a broader population.

How Does QDENGA Work?

QDENGA is administered in a two-dose schedule ¹. It is a live-attenuated vaccine, meaning it contains weakened forms of the dengue virus. When administered, these weakened viruses do not cause the disease but are sufficient to trigger an immune response. The body then develops immunity, providing protection against future infections from the wild-type dengue virus ⁹. Clinical data has shown that QDENGA provides protection for at least seven years, reinforcing its long-term safety profile and efficacy ¹.

Where is QDENGA Approved?

QDENGA has received approvals in several regions globally, marking it as a significant tool in dengue prevention.

India

In a landmark decision, India approved QDENGA in July 2026, making it the country's first-ever approved dengue vaccine ³⁵⁷. The Drug Controller General of India (DCGI) granted market authorization to Takeda Biopharmaceuticals India for the vaccine ³. This approval is particularly significant given India's substantial public health challenge posed by dengue ².

• Age Group: The vaccine is approved for individuals aged 4 to 60 years in India ⁴.
• Significance: This approval is seen as a major step in strengthening dengue prevention efforts in India, a country that accounts for nearly one-third of the global dengue burden ²⁸.

Other Regions

While the recent approval in India is a major development, QDENGA has also been approved in other parts of the world. The European Medicines Agency (EMA) has approved QDENGA for adults, adolescents, and children from 4 years of age ⁹. The World Health Organization (WHO) recommends that countries consider introducing TAK-003 into their routine immunization programs in geographical locations where high transmission intensity of dengue poses a significant public health problem ¹⁰.

Takeda is actively working to expand global access to QDENGA through partnerships with national immunization programs, private payors, and public health initiatives ¹.